The NY-based company’s advisory services include clinical development plans, product pipeline assessment, manufacturing strategy and relationships, among others.
“There is an expansive global landscape for cell and gene therapies. As momentum of these industries continues to accelerate and new therapies show remarkable results for patients, it creates an intensifying need for commercial support and readiness,” said George Goldberger, Cell One Partners founder and CEO.
Goldberger also was involved in the founding of PCT, now known as Hitachi Chemical Advanced Therapeutics Solutions, where he worked for nearly two decades.
Joining him on the leadership team is Alexander Voss, who was formerly of PharmaCell BV, now part of the Lonza Group. Rob Dickey IV and David Schloss also will, respectively, provide finance and human resources support.
“It is an incredibly exciting time for both the cell and gene therapy industries,” Goldberger told us. “We want to do all we can to help these companies achieve success. Knowing that so many patients will benefit in the not too distant future is a strong motivator.”
According to the 2018 Alliance for Regenerative Medicine’s state of the industry report, globally, there are more than 900 companies and more than 1,000 ongoing clinical trials in this area. These companies and other regenerative medicines firms raised more than $13.3bn in 2018, marking a 73% increase over 2017.
“As these companies advance therapies through discovery and development, they need assistance in key areas such as regulatory, manufacturing, reimbursement and ultimately commercialization,” said Goldberger.
Cell One Partners’ goal is to help an increasing number of companies achieve success – “which will translate to greater benefit for a broad patient population,” he added.
The company’s structure combines what Goldberger called “a hands-on client team” with a global network of strategic advisors and industry insiders.
As he explained, “Depending on the nature of the project, the core client team taps into these experts to assemble a broader, yet highly customized team with the exact set of skills, experience and expertise needed by our clients.”
“The core team can then evolve the set of advisors they leverage on behalf of the client as the client’s therapeutic candidate progresses towards approval and commercialization,” added Goldberger. “Through this model, we can become a long-term partner for our clients.”